Gilead, Arcus scrap late-stage trial of cancer drug combo

Core Viewpoint - Gilead Sciences and Arcus Biosciences have decided to halt a late-stage study of their experimental cancer drug combination aimed at treating advanced stomach and esophageal cancers due to unspecified reasons [1] Company Summary - Gilead Sciences is involved in the development of innovative therapies for cancer treatment [1] - Arcus Biosciences collaborates with Gilead Sciences in the research and development of cancer drugs [1] Industry Summary - The decision to stop the clinical trial reflects challenges in the oncology sector, particularly in developing effective treatments for advanced cancers [1] - The halt may impact investor sentiment and future research directions within the cancer treatment landscape [1]